Cardiovascular safety of fexofenadine HCl

Clinical and Experimental Allergy, Supplement

Volumn 29, Issue 3, 1999, Pages 212-216

  Pratt, C ^a   Brown, A M ^b   Rampe, D ^c   Mason, J ^c   Russell, T ^c   Reynolds, R ^c   Ahlbrandt, R ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Rammelkamp Center   (United States)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ERYTHROMYCIN; FEXOFENADINE; KETOCONAZOLE;

ALLERGIC RHINITIS; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LONG QT SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QT INTERVAL; TORSADE DES POINTES;

EID: 0032803083     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1999.0290s3212.x     Document Type: Article

References (17)

1. 1 antihistamines. Ann Allergy 1991; 67:625-33.
2. Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996; 36:233-52.
3. Hoechst Marion Roussel. Seldane, Physicians Desk Reference. Montvale, New Jersey 1997:1284-6.
4. Janssen Pharmaceuticals Inc. Hismanal, Physicians Desk Reference. Montvale, New Jersey 1997:1341-3.
5. Pratt CM, Hertz RP, Ellis BE, Crowell SP, Louv W, Moye L. Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over the counter antihistamines, ibuprofen and clemastine. Am J Cardiol 1994; 73:346-52.
6. Russell T, Stolz M, Eller M, Bhargava V, Weir S. Acute and subchronic dose tolerance of fexofenadine HCl in healthy male subjects (Abstract). Ann Allergy Asthma Immunol 1996; 76 (1):P27.
7. Bernstein D, Schoenwetter WF, Nathan RA, et al. Efficacy and safety of fexofenadine HCl for seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79:443-8.
8. 1-receptor antagonist, in the treatment of fall allergies. Allergy Asthma Proc 1997; in press.
9. Data on File. Hoechst Marion Roussel, Inc, Kansas City, Missouri.
10. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920; 7:353-70.
11. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52:231-8.
12. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269:1513-8.
13. Pratt CM, Ruberg S, Morganroth J, et al. The dose-response relationship between terfenadine (Seldane®) and the QTc interval on the scalar electrocardiogram: Distinguishing drug effect from spontaneous variability. Am Heart J 1996; 131:472-80.
14. Woolsey RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the Cardiotoxic Actions of Terfenadine. J Am Med Assoc 1993; 269:1532-6.
15. Brown AM. Cardiac potassium channels in health and disease. Trends Cardiovasc Med 1997; 7:118-24.
16. Lacerda AE, Roy ML, Lewis EW, Rampe D. Interactions of the nonsedating antihistamine loratadine with a Kv1.5-type potassium channel cloned from human heart. Mol Pharmacol 1997; 52:314-22.
17. Rampe D, Wible B, Brown AM, Dage RC. Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart. Mol Pharmacol 1993; 44:1240-5.